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Abstract | The emerging complexity of the transcriptional landscape poses great challenges 
to our conventional preconceptions of how the genome regulates brain function and 
dysfunction. Non-protein-coding RNAs (ncRNAs) confer a high level of intricate and dynamic 
regulation of various molecular processes in the CNS, ranging from neurodevelopment to 
brain ageing, from synapse function to cognitive performance, and from health to disease. 
ncRNA-mediated processes may be involved in various aspects of the pathogenesis of 
neurodegenerative disorders. Understanding these events may help to develop novel 
diagnostic and therapeutic tools. Here, we provide an overview of the complex mechanisms 
that are affected by diverse ncRNA classes that have been implicated in neurodegeneration.  
 
  
Novel high-resolution and high-throughput technologies, such as tiling arrays and deep-
transcriptome sequencing, have revealed that complex genomes give rise to noncoding 
RNAs (ncRNAs)1,2 (FIG. 1). ncRNAs are particularly abundant in the CNS3–5. It has been 
estimated that 40% of long ncRNA (lncRNAs) genes are specifically expressed in brain tissue, 
and other types of ncRNAs, such as circular RNAs (circRNAs) and certain microRNAs 
(miRNAs), have also been reported to be enriched in the CNS (and some specifically at 
synapses)6–10. Remarkably, research in the field of neurodegeneration has until now largely 
focused on a small percentage of the approximately 20,000 protein-coding genes. Protein-
coding genes occupy less than 2% of the whole genome11, which inevitably raises the 
question as to whether we are overlooking an important part of the biology that underlies 
neurodegenerative disorders. 
The functional interrogation of the rapidly increasing number of annotated ncDNA 
sequences is a formidable challenge and therefore critical experimental validation of the 
emerging evidence is required (BOX 1). Nevertheless, recent years have seen a surge of 
studies underscoring the vital roles of ncRNAs in brain evolution, development, homeostasis, 
stress responses and plasticity12–23.  Indeed, loss-of-function studies have provided examples 
of the importance of ncRNA-mediated regulation in brain function24–28. Moreover, ncRNAs in 
adult mouse brain often exhibit region- and stage-specific expression patterns29,30,  are 
dynamically regulated by neuronal activity7,8,31–35, and although most (but not all36) ncRNA 
genes are expressed at relative low levels, they may provide more information about cortical 
cell type identity than their protein-coding counterparts13,37.  
Consistent with the observations mentioned above, ncRNAs have been implicated in 
brain aging and in the pathophysiology of neuropsychiatric and neurodegenerative 
disorders5,12,13,38. In this Review, we survey the emerging roles of ncRNAs in 
neurodegeneration and discuss in which ways they challenge our understanding of 
neurodegenerative diseases and how they might lead to novel diagnostic and therapeutic 
strategies. 
 
[H1] ncRNAs in CNS homeostasis 
During CNS development, ncRNAs affect stem cell maintenance, progenitor proliferation and 
cell fate choice5,13,19,25,27,39–41. miRNAs such as miR-124 and miR-132 have a marked positive 
regulatory impact on neurogenesis42,43, while some lncRNAs, such as rhabdomyosarcoma 2 
associated transcript (RMST) and Tcl1 upstream neuron-associated long intergenic ncRNA 
(TUNA), induce neuronal differentiation17,20. Moreover, ncRNAs are implicated in neuronal 
fate commitment (for example miR-124 (REF.44), embryonic ventral forebrain 2 (Evf2) 
(REF.18), double-stranded neuron-restrictive silencer factor (dsNRSF)45 and distal-less 
homeobox 1, antisense (Dlx1AS21), in glial specification (for example, miR-219 and miR-338 
(REF.46), Sox8 opposite transcript (Sox8OT) and nuclear enriched abundant transcript 1 
(NEAT1)21, and NK2 homeobox 2 (Nkx2.2) (REF.22)) or in both (for example, miR-9 (REFs46,47) 
and Gomafu21,35).  
 A broad array of distinct ncRNA classes — such as small ncRNAs (miRNAs48, 
endogenous small-interfering RNAs (endo-siRNAs), small nucleolar (sno)-derived RNAs33 and 
PIWI-interacting RNAs (piRNAs)16, long natural antisense transcripts (NATs) 49,50), enhancer 
ncRNAs (eRNAs) 32,  circRNAs 7,8 and other lncRNAs 51 (for example, metastasis associated 
lung adenocarcinoma transcript 1 (MALAT1) and NEAT1 (REF.31) and Gomafu35)— have been 
implicated in synaptic plasticity. Synaptically enriched ncRNAs, such as certain miRNA 
precursors, various miRNAs (for example, miR-9, miR-132, miR-134 and miR-138)52,53, BC1, 
BC20013 and most brain circRNAs7,8, act as synaptic regulators in symphony with their 
protein-coding counterparts to regulate local protein expression54. A natural antisense 
transcript of BDNF (BDNF-AS) may negatively regulate synaptic plasticity by repressing the 
transcription of BDNF50, whereas another lncRNA, MALAT1, may be a positive regulator of 
synaptogenesis15. 
Epigenetic and transcriptional changes at the synapse contribute to memory 
consolidation and storage. A growing body of evidence demonstrates that ncRNA-mediated 
regulation is instrumental for memory formation 14,55,56. Small ncRNAs, including miRNAs 
14,56, piRNAs 16,55 and BC1 (REF.56), are associated with cognitive and behavioural processes. 
Research on other ncRNA classes is still in its infancy. Importantly, knocking down an 
endogenous antisense ncRNA against Ub3a, a gene imprinted in Angelman syndrome, 
rescues some of the cognitive deficits that are observed in a genetic mouse model of this 
disorder57. Although the exact regulatory impact of several identified ncRNAs on memory 
and cognition remains elusive, the available evidence suggests that ncRNA networks are 
important for CNS homeostasis and that their dysregulation could have profound 
consequences for brain function. 
 
[H1] ncRNA networks and neurotoxicity 
A number of distinct ncRNA classes are implicated in neurodegenerative disorders 
(Supplementary information S1 (table)). Aberrations in the transcriptional networks in which 
these ncRNAs operate (BOX 2) may impinge on brain homeostasis in complex ways58 (FIG. 2). 
This is well illustrated by studies of the C9ORF72-associated hexanucleotide repeat 
expansion (GGGGCC), the most common genetic cause of amyotrophic lateral sclerosis (ALS) 
and frontotemporal dementia (FTD). These repeat sequences are transcribed in both sense 
and antisense RNA and accumulate in nuclear and cytoplasmic RNA foci, whose number 
correlates with pathology severity in C9ORF72-related cases of ALS and FTD59–61. In addition, 
six dipeptide repeat proteins are translated from the C9ORF72 repeat locus (so-called 
repeat-associated non-ATG (RAN) translation) and co-aggregate in neuronal, ubiquitin-
containing, intranuclear and cytoplasmic inclusions in the brain and spinal cord, possibly 
contributing to protein-mediated neurotoxicity mechanisms62,63 (FIG. 2).  
Spinocerebellar ataxia type 8 (SCA8) is similarly caused by multiple transcriptional 
products of SCA8. The sense strand gives rise to a trinucleotide repeat expansion transcript 
and to a polyglutamine expansion protein, which accumulates in intranuclear inclusions in 
cerebellar and brainstem neurons of transgenic mice and human autopsy tissue64. Moreover, 
a pathogenic repeat sequence is transcribed in the antisense direction giving rise to a 
noncoding repeat RNA that overlaps with the Kelch-like protein 1 (KLHL1) gene (the ncRNA 
gene is known as SCA8, ataxin 8 (ATXN8) opposite strand (ATXN8OS) or KLHL1 antisense)64,65. 
Transgenic mice overexpressing the human SCA8 expansion sequence display cerebellar 
deficits and progressive motor deficits that are similar to those observed in affected 
individuals65. The accumulation of both sense and antisense expansion transcripts, and of a 
polyglutamine expansion protein in these mice, suggests that SCA8 pathology possibly 
involves both protein and RNA gain-of-function mechanisms65.  
Non-protein coding genes may also have roles alongside protein-coding counterparts 
in fragile X syndrome (FXS), Huntington’s disease (HD) and Alzheimer’s disease (AD). The 
expansion of the microsatellite locus in the fragile X mental retardation 1 (FMR1) gene is 
associated with FXS (>200 CGG repeats; termed full mutation) and the related condition 
fragile X-associated tremor and ataxia syndrome (FXTA) (55–200 CGG repeats;  termed 
premutation). This locus gives rise to four distinct transcripts with possible pathogenic 
relevance: the FMR1 repeat-containing mRNA; the FMR5 RNA, a sense ncRNA that is 
transcribed upstream of the FMR1 promoter; the FMR6 RNA, an antisense ncRNA that 
overlaps the FMR1 3’-untranslated region (UTR); and, finally, FMR4, an antisense transcript 
from FMR1 that spans the repeat region66,67 (FIG. 2). These transcripts show different 
expression patterns in the brains of individuals carrying the premutation or the full 
mutation.  
This complex transcriptional fingerprint may contribute to the variability of the 
clinical phenotypes observed in FXTAS and FXS66,67. Transcriptional silencing of FMR1 in 
patients with FXS leads to a deficit in its protein product FMRP, an RNA-binding protein that 
regulates local protein translation in dendrites. Fmr1 knockout mice display synaptic 
alterations and cognitive impairment, suggesting a causal link between FMRP loss-of-
function and FXS pathology68. However, FMR1 expansion repeat RNA co-localizes with 
ubiquitin in intranuclear inclusions in postmortem FXTAS brain67, and FMR4, which is also 
silenced in individuals with FXS, exerts antiapoptotic functions in human cell lines69,70. These 
findings illustrate the complexity of the gain- and loss-of-function mechanisms in brain 
disorders such as FXTAS and FXS.  
In HD, a CAG repeat expansion in exon 1 of the gene huntingtin (HTT) is the primary 
cause of pathology. A small sense repeat transcript (sCAG) derived from the repeat-
containing mRNA is elevated in the brains of individuals with HD and is neurotoxic in vitro71, 
indicating that it might contribute to HD pathology. However, an antisense ncRNA 
overlapping the HTT repeat locus (HTT-AS) acts as an HTT repressor and is downregulated in 
brain tissue from patients with HD72. Since lowering mutated and wild-type HTT levels 
ameliorates pathology in HD mice73, HTT-AS should have a  protective role in the disorder. 
In AD, the evidence for a role of cross-talking coding and non coding transcriptional 
networks is much less straightforward. Single nucleotide polymorphisms (SNPs) in the 
vicinity of a locus giving rise to both antisense ((antisense non-coding RNA in the INK4 locus 
(ANRIL; also known as CDKN2BAS) and circular (cANRIL) transcripts, which have been 
reported to be involved in epigenetic regulation, have been associated with AD pathology74–
77. These associations have not yet been confirmed in larger, classic genome-wide 
association studies (GWAS), but the observations may be of interest as CDKN2B, which gives 
rise to these transcripts, encodes a protein involved in cell cycle regulation that accumulates 
in neurofibrillary tangles and amyloid plaques, which are pathological features observed in 
the brains of patients with AD78. In addition, an antisense transcript of the glia-derived 
neurotrophic factor (GDNF) gene (GDNFOS),  gives rise — via alternative splicing — to two 
ncRNAs and one protein and has been implicated in aberrant GDNF mRNA splicing in human 
AD brain tissue79. The functional consequences of these events for the physiological 
neurotrophic and neuroprotective functions of GDNF and for AD pathogenesis remain, 
however, unclear. 
 
 [H1] ncRNA mechanisms in neurodegeneration 
A growing list of studies illustrates the diversity of ncRNA roles in brain function and 
dysfunction (Supplementary information S1 (table)). Gaining a deeper understanding of 
ncRNA-mediated mechanisms of regulation will eventually facilitate their efficient 
therapeutic targeting. Here, we summarize six major mechanisms that likely contribute to 
the neurodegenerative process (TABLE 1 and FIG. 3). 
 
[H3] Epigenetic regulation. Chromatin immunoprecipitation (ChIP) assays demonstrate that 
ncRNAs with links to neurodegeneration associate with chromatin remodeling complexes 
and may therefore play roles in epigenetic regulation.  
An  example is a ncRNA associated with SCA7, where polyglutamine repeat 
expansions in ATXN7 cause neurodegeneration(REF.80). . Convergent transcription of 
spinocerebellar ataxia-7 antisense noncoding transcript 1 (SCAANT1) suppresses Atxn7 
transcription in the sense direction in mice80. SCAANT1 levels inversely correlate with ATXN7 
mRNA levels in fibroblasts from patients with SCA7 and in transgenic mice carrying the 
repeat disease locus80. Hence, a feedforward regulation explanation has been proposed, 
wherein the repeat expansion in ATXN7 reduces SCAANT1 expression, which leads to de-
repression of ATXN7 transcription and increased mutant ATXN7 levels80. 
The lncRNAs BDNF-AS, TUG1, MEG3, NEAT1 and TUNA, which may act as epigenetic 
regulators, are differentially expressed in brain tissue from humans with HD versus that from 
healthy individuals17,81–83 and might be involved in the pathological outcome by modifying 
the effects of mutant HTT. In particular, BDNF-AS, which is activity-dependent, acts as a 
scaffold to recruit polycomb repressive complex 2 (PRC2) to the BDNF promoter, resulting in 
BDNF transcriptional repression in a human cell line31,50. This regulatory effect may be of 
relevance in HD, in which BDNF is downregulated in the human brain84. Interestingly, BDNF 
overexpression rescues dopaminergic, synaptic, motor and cognitive deficits in a HD 
transgenic mouse model82, and BDNF-AS inhibition provides neuroprotection upon ischemic 
insult in retinal ganglion cells85. Importantly, the regulatory effects of all the differentially 
expressed lncRNAs mentioned above still await systematic experimental validation in HD 
models17,81.  
 
[H3] RNA interference. Posttranscriptional repression of gene expression by miRNAs and 
small-interfering RNAs (siRNAs) is collectively termed RNA interference (RNAi). Key 
molecular components shared between miRNA- and siRNA-mediated mechanisms are the 
RNase III endonuclease Dicer, which has a role in the generation of miRNAs and siRNAs, and 
the argonaute (AGO) protein family, which is a core component of the RNA-induced silencing 
ribonucleoprotein complex (RISC) that brings together the ncRNA and the mRNA target86. 
miRNAs bind to their targets leading to either mRNA decay or translational inhibition. Global 
or individual manipulation of miRNA levels in the rodent brain can lead to 
neurodegenerative phenotypes26,87–89. Indeed, genetic ablation of Dicer in adult mouse brain 
promotes  hyperphosphorylation of TAU and neuronal loss in the hippocampus26, which are 
both features of AD, whereas increasing the levels of the miRNA let-7 induces neuronal 
death in the mouse cortex 88.  miRNA expression profiles are perturbed across a wide 
spectrum of neurodegenerative disorders, including AD, Parkinson’s disease (PD), HD, ALS, 
FXS, FTD and SCA (Supplementary information S1 (table)). miRNA-mediated regulatory 
networks involve multiple targets and therefore altered levels of one miRNA in the CNS 
might impact several layers of cellular homeostasis90. This is illustrated in knockdown 
experiments of miR-132, which is consistently and robustly downregulated in AD brain 
tissue90,91. In AD transgenic mice, miR-132 downregulation in the hippocampus promotes 
both the accumulation of amyloid-β (a hallmark of AD) and TAU hyperphosphorylation by 
upregulating inositol-trisphosphate 3-kinase B92. In addition, miR-132 inhibition in primary 
cortical and hippocampal neurons in vitro,, leads to the activation of the forkhead box 
protein O3 (FOXO3)–PTEN–P300 signalling pathway, which induces neuronal death93.  
Other ncRNAs may also act via the RNAi pathway. The small neurotoxic repeat-
containing transcript sCAG, which stems from HTT and is upregulated in the frontal cortex 
and caudate of brains from individuals with HD and in brain tissue from HD transgenic mice, 
is loaded into the RISC to act as a gene silencer71. Interestingly, sCAG RNAs isolated from 
cells expressing human mutant HTT and from HD-affected human brain tissue markedly 
decreased the viability of human neuronal cells via an AGO2-dependent mechanism71. 
Antisense oligonucleotides against sCAGs reversed this effect, supporting a role for sCAGs in 
mutant HTT-mediated neurotoxicity71. Conversely, the antisense ncRNA derived from the 
same HTT locus (HTT-AS) seems to repress HTT expression also via a Dicer-dependent 
regulatory mechanism. HTT-AS is downregulated in human HD brain tissue72. An interesting 
model emerges from these observations in which the presence of the repeat expansion in 
the HTT-AS transcript represses its transcription, which may result in elevated mutant HTT 
levels in HD.  
 
[H3] Alternative splicing. Shifting the splicing profiles of transcripts is another mechanism by 
which ncRNAs may affect pathology in neurodegenerative disorders. Sortilin-related 
receptor 1 (SORL1) is a risk gene for late-onset AD that regulates the trafficking of amyloid-β 
precursor protein (APP) — from which amyloid-β is derived — and can be proteolytically 
processed by β-site APP cleaving enzyme 1 (BACE1; also known as β-secretase 1), which is 
involved in amyloid-β generation94. SORL1 levels are decreased in the brains of individuals 
with AD94, and Sorl1 ablation in mice induces amyloid-β formation by shifting APP from the 
retromer recycling pathway to the BACE1 proteolytic pathway 95. An antisense transcript 
termed SORL1-AS (also known as 51A) shifts splicing so that transcripts for the alternative B 
and F isoforms of SORL1 are produced over the transcript for the canonical, long SORL1 
isoform A, leading to downregulation of canonical SORL1. This shift in splicing is associated 
with increasing amyloid-β levels in cultured human neuronal cells94. Notably, SORL1-AS is 
upregulated in human AD cortex, suggesting that it might contribute to the SORL1 deficit 
and elevated amyloid-β production that are observed in the disease.  
Another ncRNA that may be involved in AD, at least in part, through alternative 
splicing is the lncRNA 17A. This ncRNA is also upregulated in AD brain tissue96 and may have 
a dual impact, as it increases amyloid-β generation and induces alternative splicing of 
GABAB2, which encodes GABAB receptor subunit 2, abolishing signalling mediated by 
receptors containing this subunit in neuroblastoma cells in vitro 96. 
In SCA8, ATXN8OS accumulates in RNA foci in the brain97. ATXN8OS promotes 
alternative splicing of the sodium- and chloride-dependent GABA transporter 4 gene (Gabt4) 
and increased expression of the encoded protein in SCA8 transgenic mice97, and such 
changes are also observed in autopsy-obtained brain tissue from patients  with SCA897.  
Increased GABT4 levels have been linked to a reduction of GABA at synapses in cerebellar 
granular neurons97. In SCA8 transgenic mice, ATXN8OS was implicated in loss of GABAergic 
inhibition in the cerebellar granular cell layer and induction of a progressive motor 
phenotype, linking a RNA gain-of-function mechanism directly to SCA8 pathology97. 
ATXN8OS might also regulate the splicing of its sense transcript, the mRNA for KLHL165, 
although the relevance of this effect to disease pathology is unknown. 
Finally, the widespread alterations in FMR1 splicing profiles in the brain in FXS 
suggest that FMR6, a natural antisense FMR1 transcript that is downregulated in FXS brains, 
regulates the canonical splicing of FMR1 (in addition to other effects)66. The functional 
validation of these observations may provide further insights into disease pathology. 
 
[H3] mRNA stability. Cytoplasmic RNA–RNA duplex formation between naturally occurring 
antisense and cognate sense transcripts can prevent endo- or exonucleolytic degradation of 
the sense mRNA, or block access to proteins involved in RNA turnover, increasing its stability 
and translation98. For example, the BACE1 antisense ncRNA (BACE1-AS) binds BACE1 mRNA, 
leading to increased BACE1 levels in human cell lines and mouse brain. As indicated above, 
BACE1 is one of the proteases that generate amyloid-β, and it has become a major drug 
target that is being currently explored in phase 3 clinical trials for AD. BACE1-AS is elevated 
in the brains of individuals with AD and of some transgenic mouse models of the disease99. 
Moreover, it is increased upon exposure to amyloid-β in vitro99, suggesting that a possibly 
deleterious positive feedback loop involving BACE1-AS and amyloid-β may be maintained 
during AD progression. 
In contrast to BACE1-AS, ciRS-7 (also known as CDR1-AS) is a strongly brain-enriched 
circular antisense ncRNA100 that is downregulated in the cortex and hippocampus of patients 
with sporadic AD101. This ncRNA has mainly been studied for its role as a molecular decoy, 
which is discussed below. However, ciRS-7 also stabilizes — via an as yet unknown 
mechanism — its sense transcript, the mRNA for cerebellar degeneration-related antigen 1 
(CDR1), which was first identified in patients with paraneoplastic cerebellar degeneration100. 
Of note, one preliminary report suggested that CDR1 might be increased in lymphocytes 
from patients with AD, but the importance of this observation for AD pathology in the 
human brain remains unclear102. 
Another example of a potentially disease-linked, mRNA stability-related mechanism 
concerns an antisense transcript from the PTEN-induced putative kinase 1 (PINK1) locus 
(PINK1-AS). Mutations in PINK1 are causally related to PD103, and PINK1-AS positively 
regulates the abundance of a specific splice variant of PINK1 (svPINK1) in neuroblastoma 
cells, possibly via RNA–RNA hybridization and transcript stabilization104.  
Last, FMR6, which has already been discussed above, might stabilize FMR1 mRNA66. 
The findings relating to FMR6 and indeed PINK-AS, suggest that this ncRNA-mediated 
regulation of disease-associated protein-coding transcripts might theoretically impact the 
activity of the related proteins and thereby modify disease progression, although this 
hypothesisrequires further experimental validation in disease models.  
 
[H3] Translational regulation. Certain ncRNAs have a direct impact on the translation of 
mRNA transcripts. BC200, a small neuron-specific ncRNA, is transported in ribonucleoprotein 
particles to the dendrites where it forms part of a complex with multiple protein interactors 
(including FMRP) that regulates the translation of several mRNAs in mouse brain105. Given 
that local translation in dendrites is involved in long-term synaptic plasticity and that BC200 
levels markedly increase in human AD brain, it is intriguing to hypothesize that BC200 might 
be implicated in the synaptic defects that are observed in AD 106.  
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1) is a brain-enriched protein 
that is highly expressed in the substantia nigra and that is involved in dopaminergic neuron 
differentiation and in the ubiquitin-proteasome system. GWAS indicate that UCHL1 is a PD 
risk gene107. An antisense transcript for this gene (UCHL1-AS) targets Uchl1 mRNA to heavy 
polysomes for translation, resulting in increased UCHL1 levels108. In in vitro PD models, both 
UCHL1-AS and Uchl1 mRNA are downregulated, suggesting a possible link to the 
proteasomal deficits that are observed in PD109.   
 
[H3] Molecular decoys. Owing to their highly versatile, modular nature, ncRNAs can act as 
molecular traps that titrate away an RNA (in this context the ncRNAs are called competing 
endogenous RNAs (ceRNAs)110) or a protein target111, or transport them to specific cellular 
compartments. The relative abundance of the ncRNA decoy and of its targets along with the 
number of target molecules that can be sequestered by one single ncRNA in a given cellular 
context are critical factors that determine the outcome of such interactions112,113. More 
specifically, the concentration of the ceRNA must approach that of the target miRNA to 
induce meaningful de-repression of the miRNA targets113,114.  
The hexanucleotide repeat-containing C9ORF72 sense transcript, which is involved in 
FTD and ALS, co-accumulates with the antisense C9ORF72 ncRNA in nuclear and cytoplasmic 
RNA foci in human cultured cells and in patient brain tissue60,63. Several RNA-binding 
proteins can be sequestered in these foci in brain tissue from humans with FTD or ALS and 
from mice with this expansion mutation, leading to altered RNA splicing or perturbed 
nucleocytoplasmic transport and possibly contributing to certain aspects of the 
pathology63,115.  
The ncRNAs MALAT1 and NEAT1 are elevated in the brain of patients with FTLD-TDP, 
where they are the two most  highly detected RNAs in TAR DNA-binding protein 43 (TDP43)-
positive disease-associated inclusions116. In mammalian cells, MALAT1 and NEAT1 are 
implicated in recruiting splicing factors to subnuclear bodies called speckles and 
paraspeckles, respectively116,117. These observations clearly suggest that splicing aberrations 
contribute to disease, although the extent to which they influence the progression of 
pathology needs further assessment. This is also the case for the antiapoptotic transcript 
FMR4 (the antisense transcript of FMR1), which is highly expressed in individuals with FXTAS 
and silenced in FXS, and sequesters RNA-binding proteins into intranuclear inclusions in 
cultured human cells67,69.   
The antisense ncRNA LRP1-AS can act as a molecular decoy for the ubiquitous 
chromatin-associated protein HMGB2, serving as a cell type- and locus-specific natural RNA 
ligand to fine tune HMGB2 activity in vitro118. This interaction obscures the binding of 
HMGB2 to its target LRP1, resulting in reduced Lrp1 transcription. Interestingly, LRP1-AS is 
upregulated in the superior frontal gyrus in brain tissue from patients with AD and its levels 
are inversely correlated with LRP1 levels118. Although cell biology studies suggest a role for 
LRP1 in amyloid-β metabolism in brain, the relevance of LRP1 regulation by LRP1-AS in AD 
pathology remains to be clarified. 
The aforementioned circular RNA ciRS-7 represents a unique example of 
multifunctionality. Notably, ciRS-7 is expressed at 200-fold higher levels than housekeeping 
proteins in human and mouse brains100,114, suggesting that ciRS-7-mediated molecular 
trapping mechanisms in CNS are stoichiometrically relevant. Apart from stabilizing CDR1 
mRNA, as discussed above, human ciRS-7 harbors 74 seed sequence matches for miR-7 
(which reflects a 10-fold higher miRNA-binding capacity than any other known transcript) 
and acts therefore as a miR-7 ‘sponge’ in neuronal tissues114,119. In brains from AD patients, 
decreased ciRS-7 levels in the hippocampus and the cortex are associated with miR-7 
upregulation and consequent repression of miR-7 targets involved in ubiquitin-mediated 
clearance of amyloid-β101. In vitro, ciRS-7 promotes APP and BACE1 degradation by both the 
proteasomal and the lysosomal pathways, leading to decreased amyloid-β levels120. Hence, a 
complex link is emerging between ciRS-7 deficits and pathological amyloid-β aggregation in 
the AD brain. Moreover, since one of the targets of miR-7 is α-synuclein mRNA, which is 
encoded by SNCA, this regulatory network might have a role in PD as well121 (α-synuclein is 
implicated in the pathophysiology of PD). Interestingly, endogenous α-synuclein mRNA levels 
decrease upon transfection of a human cell line with miR-7, a change that is counteracted by 
overexpression of ciRS-7 (REF.114). ciRS-7 is degraded in a miR-671-dependent manner 
(possibly following direct ciRS-7–miR-671 base pairing) via AGO2-mediated cleavage in a 
human cell line100, suggesting that ciRS-7 acts to transport a cargo of miR-7 that becomes 
released by miR-671. Such spatiotemporal control of miR-7 activity in the cell might go 
astray in neurodegeneration. 
Finally, lnc-SCA7 acts as a miRNA decoy to regulate ATXN7 mRNA in a brain region-
dependent manner122. More specifically, lnc-SCA7 competes with the ATXN7 transcript for 
binding to miR-124, thereby increasing ATXN7 levels in mouse and human neuroblastoma 
cells. Further experimental confirmation of these findings is required, as disruption of this 
tripartite regulation might play a role in SCA7 pathology, in which the levels of expansion 
repeat-containing ATXN7 are elevated122. 
 
[H1] Genetic associations  
Only 7% of the nearly 6,500 disease- or trait-predisposing SNPs that have been identified in 
more than 1,200 GWAS over the past decade are located in protein-coding regions, 
suggesting that most of these GWAS-associated SNPs regulate gene expression rather than 
altering the protein sequence or structure123. Interestingly, 75% of the SNPs that affect 
lincRNA expression do so in a tissue-dependent manner and without influencing the 
expression of neighbouring protein-coding genes123.  Nevertheless, hard genetic proof for a 
causal role of SNPs in ncRNA transcripts or ncRNA-interacting genomic loci in 
neurodegeneration is lacking (Supplementary information S2 (table)). For instance, a 
polymorphism in the 3’-UTR of oxidized low density lipoprotein receptor 1 (OLR1) mRNA 
may impair amyloid-β clearance from the brain across the blood–brain barrier (BBB) and was 
associated with cerebral amyloid angiopathy in a small cohort of patients with AD124. 
Moreover, a variation in the miR-433-binding site of FGF20 induces the expression of both 
FGF20 and α-synuclein and is associated with increased risk for PD125.  
FTLD-TDP can be caused by loss-of-function mutations in progranulin (GRN). A 
genetic variant in a binding site for miR-659 in the 3’-UTR of GRN mRNA increases the 
binding of the miRNA to its target, resulting in stronger GRN repression; this variant has 
been reported by some studies to be a susceptibility factor for FTLD-TDP, AD and 
hippocampal sclerosis, although these findings require further confirmation by independent 
reports126–130. In another small-sized study, a similar polymorphism in one of miR-146a-5p 
precursors was associated with a genetic predisposition for AD131. This polymorphism 
represses miR-146a-5p expression and consequently de-represses its target TLR2, which has 
been functionally implicated in amyloid-β-dependent inflammatory signalling cascades131.  
Recent findings suggest that SNPs in noncoding enhancer regions that are in close 
proximity to disease-associated loci (for example, SNPs in the SNCA locus, which is linked to 
PD risk) may potentially affect gene expression in an organ-specific fashion, resulting in 
distinct disease phenotypes132,133. Limited knowledge about the key functional elements in 
genes coding for ncRNAs and the rules of interaction among them, and the overall lack of 
conservation of ncRNAs across different species obstruct the functional validation of genetic 
variations in these loci134. Indeed, developing an understanding of the molecular 
mechanisms governing ncRNA involvement in disease is dauntingly hard, as SNPs in ncRNA 
genes could alter ncRNA expression or structure, and/or their functional interactions with 
DNA, RNA or protein partners.  
 
[H1] ncRNA diagnostics and therapeutics  
 
[H3] ncRNAs as biomarkers in neurodegenerative disorders. Alterations in miRNA levels in 
cerebrospinal fluid (CSF) and peripheral tissues in neurodegenerative disorders have been 
extensively documented135–143. Although it is clear that miRNAs are markedly dysregulated in 
various neurodegenerative processes, most studies in this area have been monocentric and 
relatively limited with regard to sample size. Differences between studies in standardization 
of sample stratification, collection, processing, data normalization and analysis136 explain 
why these reports have not yet yielded a consensus on which of the altered miRNAs are 
relevant to disease. For instance, postmortem delays in sample collection can be crucial, as 
miRNA levels in postmortem CSF may not correlate well with those in brain owing to 
compromised BBB integrity, which can result in the rapid entry of brain miRNAs in CSF137. 
The need for systematic and standardized approaches to profile circulating miRNAs in CSF 
and blood is evident.  
Recent findings suggest that miR-206 levels (upregulated in the brain in AD) can be 
measured in olfactory mucosa in patients with mild cognitive impairment and that the 
expression of this miRNA correlates with the degree of cognitive deficit. These observations 
could prove exciting in the context of the early diagnosis of AD, as this approach may allow 
access to the molecular changes occurring in living cells144.  It should be noted, however, 
that only 41 patients were investigated in this monocentric study, so further confirmation of 
these results is needed144. In patients with ALS or FTD, sense and antisense C9ORF72 RNA 
foci have been found in fibroblasts and lymphoblasts61,62, and polyglutamine proteins have 
been detected in CSF145, suggesting the potential of these RNA and protein species as 
possible biomarkers. Again the relative low number of cases investigated (fewer than 10 
cases per study) makes it imperative to repeat these studies in much larger patient cohorts 
to gain confidence in their diagnostic potential. 
Although ncRNAs seem to be quite stable in body fluids (owing to their secondary 
structures)1,7, further study is warranted to evaluate their potential as neurodegeneration 
biomarkers146. Efforts to set up large, multicentric and well-controlled studies to document 
ncRNA alterations in CSF and blood in a systematic way are necessary147.  
 
[H3] Novel ncRNA-based therapies in neurodegeneration. Targeting ncRNAs might offer 
effective approaches for the treatment of neurodegenerative disorders12. Successful 
targeting of lncRNAs will presumably be difficult because of their extensive secondary 
structures146; however, improved oligonucleotide design has delivered multiple chemically 
modified analogues that may overcome such limitations148, and several of these tools have 
been successfully employed in experimental models of neurodegeneration149. Antisense 
oligonucleotides (ASOs) against the repeat-containing C9ORF72 transcripts and small 
molecules that inhibit RNA translation suppressed RNA foci formation in patient fibroblasts 
and in neurons derived from induced pluripotent stem cells from individuals with ALS. In 
C9ORF72 repeat-overexpressing mice, ASOs improved cognitive deficits61,145,150–153. 
Furthermore, cleavage (siRNA) or inhibition (antagoNAT) antisense strategies against NATs 
potentially involved in AD and HD modulated the levels of both the NAT and its cognate 
sense mRNA in mouse and human cell lines and in mouse brain50,99,148. Interestingly, 
inhibition of BACE1-AS lowered amyloid-β levels and improved adult neurogenesis in a 
mouse model of AD154, and an antagoNAT against BDNF-AS increased endogenous BDNF 
levels and promoted neuronal growth and survival in wild-type murine brain50. Finally, 
emerging evidence suggests that blocking the generation of certain circRNAs may counteract 
TDP43-mediated cytotoxicity, and this was suggested as a potential therapeutic strategy for 
ALS155.  
A major advantage of single-stranded oligonucleotides, such as antagoNATs and 
ASOs, is that they can be administered systemically as ‘naked’ molecules (that is, without the 
requirement for any delivery vehicles)148. Direct administration of oligonucleotides to the 
CNS has been achieved via intracerebroventricular or intrathecal infusion of CSF into rodents 
and non  human primates in tauopathy, HD, ALS and spinal muscular atrophy (SMA) animal 
models73,148,156–160. These approaches demonstrated that ASOs delivered in CSF efficiently 
enter the brain, where they engage their RNA targets leading to up- or downregulation of 
the targeted transcripts or to shifts in splicing profiles and, eventually, to the amelioration of 
tissue toxicity and cognitive deficits.  
Other emerging strategies for targeting the CNS include nanotechnology-based drug 
delivery systems. For instance, exosomes, which are nano-vesicles of endocytic origin, 
efficiently mediate the intercellular transfer of siRNAs, miRNAs and miRNA antisense 
oligonucleotides in vitro161–163. In vivo, intravenous delivery of autologous dendritic cell-
derived exosomes engineered for neuronal targeting and loaded with an siRNA against 
BACE1 resulted in marked brain-specific BACE1 mRNA and protein knockdown and a 
reduction in amyloid-β in the cortex of treated mice164. The efficient and tissue-specific 
delivery along with the absence of overall immune responses underline the potential for 
using such RNA-based systemic therapeutic approaches in chronic neurodegenerative 
conditions.  
These findings have not gone unnoticed by the pharmaceutical industry and several 
companies are now focusing on ncRNAs (miRNAs, NATs and lncRNAs) as potential 
treatments for various neurological disorders 146,165. Most of the practical attempts are still 
in the lead optimization phase, with only a few (against hepatitis C, lymphoma and fibrosis) 
having reached Phase 1 and 2 clinical trials. Apart from the great hurdle of efficiently 
crossing the BBB (which is common to all CNS-targeting drugs), ncRNA-based therapeutics 
are additionally facing the issue of the differential targeting of the multiple transcriptional 
products generated by the same target locus and the associated complex biology. 
Nevertheless, clinical trials in patients with ALS or SMA that involve intrathecal delivery of 
ASOs against protein-coding transcripts have demonstrated the promise of therapeutically 
targeting RNA166,167. Most notably, infants with type 1 SMA (the most severe form of the 
disease) that were enrolled in a recent Phase 3 clinical trial showed markedly improved 
motor function following treatment with an ASO that interferes with the splicing of the 
transcript encoding SMN2, thereby boosting the levels of the SMN2 protein167.  
 
[H1] Perspectives 
Despite substantial progress in understanding ncRNA biology and its contribution to disease, 
we can safely state that we are in the early days of this field. The vast majority of the 
annotated ncRNAs have not been functionally investigated and many questions remain 
unanswered regarding the impact of ncRNAs in the context of neurodegeneration. The only 
way forward is to perform more basic research to address the role of different ncRNAs in the 
brain, in specific brain areas, and in distinct cells. Larger, higher-powered and better-
controlled ncRNA-profiling screens in human patients in CSF, blood and, indeed, brain are 
needed to map the changes in ncRNAs in disease with greater confidence 147. In the 
meantime, novel insights, regarding mitochondrially encoded ncRNAs, ncRNA editing 
(epitranscriptomics) and epigenetic regulation of ncDNA,  continue emerging 40,168,169. 
Systems biology and bioinformatic approaches are necessary to unravel the highly intricate 
networks in which ncRNAs operate170,171. This will also require the implementation of novel 
experimental approaches, such as the currently rapidly evolving technologies to screen the 
transcriptome at the single-cell level 37 or in different spatial contexts172. Looking ahead to 
the next decade, we anticipate that valuable insights will be gained into how these 
fascinating molecules contribute to hitherto unknown aspects of pathogenic mechanisms 
and how they may be critical to understanding the human-specific aspects of neurological 
diseases (BOX 3). Finally, we will hopefully witness impovements in the diagnosis and 
treatment of neurodegenerative disorders resulting from our developing understanding of 
ncRNAs.  
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Box 1 | Technologies to probe ncRNA functions 
Experimental validation of functional associations between noncoding RNAs (ncRNAs) and 
tissue homeostasis or disease is an absolute requirement for further progress in the field. 
Addressing functionality is more difficult for the noncoding part of the genome than it is for 
protein-coding genes. The functional redundancy, low sequence conservation, nuclear 
localization and genomic overlap of ncRNAs with other coding or noncoding sequences 
hamper their functional annotation173,174. Nevertheless, a plethora of novel techniques is 
now available to study ncRNAs. Direct visualization of long ncRNAs in single cells and at 
single-molecule resolution using RNA-fluorescence in situ hybridization (RNA-FISH) has 
yielded precise cellular and subcellular expression patterns for these molecules that may 
point towards distinct functional roles for ncRNAs175,176. For instance, the particular 
localization of a ncRNA close to its own site of transcription inside the nucleus may suggest a 
role in the transcriptional regulation of a proximal locus175,177.  In addition high-resolution 
subcellular visualization of lncRNAs has unveiled a role for NEAT1, MALAT1 and MIAT in the 
formation of nuclear bodies (speckles and paraspeckles)175,176,178. Novel RNA-interactome 
approaches coupled to high-throughput sequencing allow in vivo identification of functional  
partners of ncRNAs. ChIRP-seq (chromatin isolation by RNA purification-sequencing), CHART 
(capture hybridization analysis of RNA targets) and RAP (RNA antisense purification) are 
employed for lncRNA–chromatin complex purification and identification of ncRNAs involved 
in topologically associating domains and nuclear organization 176,179–181; ChIRP-MS (ChIRP-
mass spectrometry) and RAP-MS (RAP-mass spectrometry) are used for assessing RNA-
protein interactions 182–185; and CLASH (cross-linking, ligation and sequencing of hybrids) for 
RNA-RNA pairing 179. In addition, several modified versions of each of these technologies 
such as dChIRP (domain-specific ChIRP) 186 and iDRiP (identification of direct RNA interacting 
proteins (iDRiP) 187 ), are emerging. Probing the secondary structure of ncRNAs using SHAPE-
seq (RNA-selective 2’-hydroxylacylation and primer extention-sequencing), PARS (parallel 
analysis of RNA structure) or FragSeq (fragmentation sequencing)188 and mapping the 
tertiary structure of ncRNA-protein complexes by high-throughput technologies such as 
CLIP-seq (cross-linking and immunoprecipitation-sequencing)182, RNA-MaP (RNA-massively 
parallel array) and RNA-MITOMI (RNA-mechanically induced trapping of molecular 
interactions) can provide key insights into ncRNA function179,189. Assigning functional roles to 
ncRNAs requires loss-of-function approaches. Many were adapted from the mRNA world. 
Chemically modified antisense oligonucleotides, such as antagomiRs or other synthetic 
molecules, such as miRNA sponges190 and miRNA zippers191 against miRNAs, and siRNAs, 
antagoNATs and ASOs against lncRNAs174, have been successfully used to knockdown 
ncRNAs and unveil their functional roles in the cell. However, there are several limitations 
when performing ncRNA loss-of-function studies. siRNA approaches, for instance, turn out to 
be less effective when targeting nuclear transcripts, which is often the case for 
lncRNAs173,174. Novel site-specific genome engineering based on TALEN (transcription 
activator-like effector nucleases) and the all-dominating CRISPR/Cas9 (clustered regularly 
interspaced short palindromic repeats/CRISPR-associated protein-9 nuclease) technologies 
are used to ablate whole ncRNA loci or their regulatory domains173,174,192,193. Selective 
excision of the full or partial ncRNA sequence is not feasible when the ncRNA intersects 
other genes or when it is transcribed from bidirectional promoters, which would alter the 
transcription of neighbouring genes174. Moreover, the regulatory domains of lncRNA genes 
remain largely uncharacterized and therefore domain-specific targeting is not always an 
option. Finally, in several cases, lncRNAs exert their function via the process of transcription 
per se, and therefore targeting the transcriptional product may not lead to a loss-of-function 
phenotype173,174. Interestingly, a recent study demonstrated that only one-third of the 
lncRNA loci are amenable to CRISPR applications without affecting additional genes174. 
Therefore, phenotypes are best confirmed using orthogonal approaches, such as siRNA, 
ASOs and CRISPR. 
 
 
  
BOX 2 | Noncoding transcriptome: from linear to three-dimensional network-based 
thinking  
The genome does not follow simplistic human-created rules, hence, the dichotomy between 
‘coding’ and ‘noncoding’ genes is an oversimplification, as we discuss in the main text194. In 
fact, protein-coding and noncoding transcribed domains from intergenic, intronic and 
intragenic regions and from both positive (sense) and negative (antisense) strands5 illustrate 
the highly interlaced structure of the genome and its transcriptome194. Accordingly, RNA 
transcribed from a single DNA locus has multiple embedded functions and can give rise to 
several functional products194 (FIG. 2). For instance, many protein-coding genes can be 
transcribed in the antisense orientation (bidirectional transcription) and/or into circular 
transcripts98,195,196. Similarly, lncRNAs often encompass small open-reading frames (ORFs) 
and are sometimes associated with ribosomes, suggesting that they might be involved in de 
novo protein synthesis197,198, although this possibility remains controversial13,199,200. 
Nevertheless, the ability to encode small peptides has been experimentally validated for 
certain primary miRNA transcripts in plants201, microsatellite repeat expansions202, large 
intergenic ncRNAs (lincRNAs)203, natural antisense transcripts(NATs)98 and for the more 
recently identified circular RNAs (circRNAs)196,204,205. 
Continuous research has yielded an inventory of tens of thousands of ncRNAs206. The 
arbitrary designation of ‘small’ or ‘long’ (cut-off set at 200-400 nucleotides) has no functional 
foundation but rather reflects the technical aspects of biochemical RNA fractionation 
approaches. ncRNAs are expressed in a highly cell type-, subcellular compartment-, 
developmental stage- and environmental context-dependent manner41,207, and their flexible 
modular nature allows them to develop RNA–RNA, RNA–DNA and RNA–protein 
interactions12.  
However, the question of what percentage of ncRNAs in the genome is really 
functional remains a matter of both semantic (when is a transcript defined as ‘functional’?) 
and pragmatic (how much of the genome is implicated in evolutionary relevant trait 
specification, biological function or  human-specific pathologies?) debate208–211.  
 
  
BOX 3 | ncRNAs as putative evolutionary signals of human brain development, ageing and 
neurodegeneration 
The degree of organismal complexity correlates better with the proportion of ncRNAs in the 
genome than with the number of protein-coding genes (even when alternative splicing and 
posttranslational modifications are considered as effectors of protein diversification)25,212–
214. This suggests that the evolution of biological complexity in eukaryotes largely stems from 
the increasing complexity of ncRNA biology214–216. ncRNA genes exhibit positive selection, 
accelerated evolution, species lineage-related expansion and specificity, preferential 
expression in brain and selective association with neural genes36,217–220. An appealing 
hypothesis is that ncRNAs may be mediators of certain behavioural and cognitive traits of 
higher organisms207, as opposed to CNS proteins, which are (apart from some limited 
examples of innovations in proteins) almost perfectly conserved across mammalian 
phyla13,54,221–223. Illustrating these principles, the rapidly evolving, brain- and human-specific 
ncRNA  HAR1F (human accelerated region 1F) is transcribed from a genomic region that has 
been subject to intense positive selection since human divergence from the great apes 224 
and along with several Piwi-interacting RNAs (piRNAs), lincRNAs, miRNAs and circRNAs is 
associated with human-specific brain development and function 195,207,219,225,226.  
A genome-wide transcriptomic analysis in rat brain revealed that changes in ncRNA 
expression patterns are more prominent than changes in mRNA expression patterns during 
ageing227. ncRNAs with important functions in synaptic and other homeostatic processes, 
such as miRNAs228, lncRNAs229, BC200 106 and circRNAs, are differentially regulated in the 
ageing human brain. Moreover, the notion that the histopathological outcomes of brain 
ageing display profound differences across species raises the intriguing possibility that 
ncRNA-mediated regulation may be implicated in ageing-associated human neurological 
conditions230. The features of progressive mild atrophic brain alterations that mammalian 
laboratory models display are distinct from clinical neurodegenerative disorders associated 
with advanced ageing, such as cerebrovascular disease, AD and PD230. Notably, no species 
except humans have shown evidence of major neuronal loss or massive cognitive decline 
that could compare to clinical grade AD230, observations that cannot be attributed to primary 
structure differences of key protein players. The sequences of amyloid-β peptide (the main 
constituent of the amyloid plaques in AD)231, MAPT (the gene for tau, which precipitates into 
neurofibrillary tangles in tauopathies and AD)232, and the genes encoding α-synuclein (which 
is implicated in PD)233 and huntingtin (which is implicated in HD)234 are almost identical in 
humans and other primates and overall highly conserved among vertebrates. The existence 
of a human-specific natural antisense transcript (PINK1-AS) that is implicated in PD104, 
human-specific antisense ncRNA regulation of the ataxin-7 (ATXN7) locus in SCA7 80, and the 
human-specific repression of HAR1 by REST along with its downregulation in the striatum of 
HD patients 235 suggest that the evolutionary non-conserved ncRNAs might have an 
important contribution to human-specific neurodegenerative disorders. Clearly, more 
experimental evidence is required to support these observationss; however, this will not be 
straightforward and classic rodent systems may have to be replaced with more relevant 
‘humanized’ models of neurodegeneration236.  
 
  
Figure 1 | Abundance of annotated loci in human genome. Protein-coding genes account 
for approximately one third of all annotated genes, whereas long and small ncRNA genes 
together provide 40% of the gene set. Pseudogenes (genes derived from protein encoding 
loci, which have lost their coding potential, but may still exert regulatory functions) are not 
discussed here, but are also present at high abundance. Numbers are derived from 
GENCODE, release 26 (http://www.gencodegenes.org/releases/current.html). 
 
  
Figure 2 | A three-dimensional transcriptional ‘code’ implicated in neurodegeneration. The 
figure depicts examples of pervasive transcription in loci implicated in neurodegeneration 
that may induce neurotoxicity via distinct and/or overlapping mechanisms. C9ORF72 gives 
rise to a sense, non-repeat-containing, protein-coding transcript and two repeat-containing 
ncRNAs (one in the sense and one in the antisense direction). Six dipeptide repeat proteins 
(repeat-associated non ATG (RAN) polydipeptides) are translated from the repeat-containing 
transcripts and accumulate in toxic intracellular foci. Three neurotoxicity-inducing 
mechanisms have been put forward in C9ORF72-related ALS and FTD 63: C9ORF72 loss-of-
function, C9ORF72 repeat expansion-related RNA gain-of-function, and generation of toxic 
dipeptide repeat proteins. Apart from a loss-of-function of FMRP, the protein encoded by 
the FMR1 locus, RNA toxic gain-of-function has been also implicated in FXS 237. The FMR1 
locus generates three sense transcripts (one protein-coding and two noncoding transcripts) 
and two antisense noncoding transcripts. A third example is the sense linear protein-coding 
and antisense circular ncRNA (ciRS-7, acts as a miR-7 sponge) that are both transcribed from 
the CDR1 locus. ciRS-7 downregulation (RNA loss-of-function) in human AD brain has been 
associated with deficits in ubiquitin-mediated amyloid-β clearance in AD 101,120. Angled 
arrows indicate the direction of transcription of sense and antisense transcripts. ncRNA 
transcripts can have a feedback regulatory effect on the protein coding mRNAs (dotted 
lines). The combinatory transcriptional outcome of each locus affects the homeostatic 
balance in CNS and its disruption can impact neurodegenerative processes. 
 
  
Figure 3 | ncRNA mechanisms in neurodegeneration. ncRNAs associated with 
neurodegenerative disorders may act at multiple functional levels to regulate a spectrum of 
molecular processes. ncRNAs can act as scaffolds to recruit transcriptional activators or 
repressors to chromatin-modifying complexes close to gene promoters and epigenetically 
regulate gene expression in the nucleus.  ncRNA regulation can induce preferential inclusion 
or exclusion of exons thereby shifting mRNA splicing patterns towards certain alternatively 
spliced isoforms.  ncRNAs in both the nucleus and the cytoplasm can bind proteins and other 
RNA molecules (for example, mRNAs, lncRNAs and miRNAs) to titrate them away from their 
physiological places of function or guide them to different intracellular compartments. 
Binding of ncRNAs onto protein-coding transcripts may affect the stability of the latter and 
either protect them from degradation (mRNA stability) or induce their decay by, for 
instance, employing the cellular components of RNA interference (RISC). Translational 
induction or inhibition is another regulatory outcome of ncRNA–mRNA interactions in the 
cytoplasm. ncRNA, noncoding RNA; DRPs, dipeptide repeat proteins; Pol II, RNA polymerase 
II; RISC, RNA-induced silencing complex 
 
 
  
Table 1 | ncRNAs involved in neurodegenerative disorders  
 Epigenetics RNAi Splicing mRNA 
stability 
Translation Sequestration 
AD ANRIL 75 miRNA 238 SORL1-AS 94 
17A 96 
BACE1-AS 99 
ciRS-7 100 
BC200 105 LRP1-AS 118 
SCA SCAANT1 80 miRNA 228,239 ATXNOS 97   lnc-SCA7 122 
PD ND miRNA 240  PINK1-AS 104 UCHL1-AS 108 ciRS-7 114 
FXS/ 
FXTAS 
 miRNA 241,242 FMR6 66 FMR6 66  FMR4 67,69 
HD BDNF-AS 81  
TUG1 81 
MEG3 81 
NEAT1 81 
TUNA 81 
miRNA 243–246 
HTT-AS 71,72 
    
FTD/ALS  miRNA 247    C9ORF72 63,115 
MALAT1 116 
NEAT1 116 
 
AD, Alzheimer’s disease; SCA, spinocerebellar ataxia; PD, Parkinson’s disease; FXS, fragile X 
syndrome; FXTAS, fragile X-associated tremor/ataxia syndrome; HD, Huntington’s disease; 
FTD, frontotemporal dementia; ALS, amyotrophic lateral sclerosis 
 
 
 
 
  
Glossary 
 
[Au: Please add glossary definitions here in the order in which the terms first appear in the 
text (main text then display items). I’ve highlighted some terms in blue or in comments 
boxes in the text that I feel would benefit from such definitions. Other terms of course 
could also be defined. Note that the term in the glossary should match the term used in 
the text exactly and the definition should ideally be no more than a sentence. No 
references can be cited in glossary definitions.] 
Long ncRNAs 
Non protein-coding transcripts longer than 200-400 nucleotides including multiple diverse 
RNA species 
Circular RNAs 
Covalently closed, single-stranded transcripts produced by back-splicing of exons in 
precursor mRNAs 
microRNAs 
Small (20-25 nucleotides) non protein-coding regulatory RNA molecules involved in 
posttranscriptional regulation 
Endogenous small-interfering RNAs  
Small (21-26 nucleotides) non protein-coding regulatory RNAs produced from endogenous 
double-stranded RNA precursors and involved in posttranscriptional silencing 
Small nucleolar (sno)-derived RNAs  
Small (17-30 nucleotides) non protein-coding regulatory RNAs that are derived from the 
processing of small nucleolar RNAs and are implicated in gene silencing 
PIWI-interacting RNAs 
Small (26-33 nuletides) non protein-coding regulatory RNAs involved in epigenetic and 
posttranscriptional gene silencing via interaction with PPIWI proteins 
Long natural antisense transcripts  
Long (>200-400 nucleotides) RNA molecules that are transcribed from the opposite DNA 
strand, they partially overlap with the sense transcript and often regulate its transcription, 
splicing or stability 
Enhancer ncRNAs  
Non protein-coding RNAs that are transcribed from enhancer DNA loci and are implicated in 
the regulation of gene transcription 
Convergent transcription 
The simultaneous transcription from two closely positioned promoters in the sense and 
antisense orientation with the RNA polymerases heading towards each other 
FTLD-TDP 
Frontotemporal lobar degeneration with tau-negative, ubiquitin-positive inclusions which 
contain TAR DNA-binding protein 43 (TDP-43)  
 Seed sequence 
Nucleotides 2-7 in the 5’-end of the miRNA sequence that are crucial for recognizing and 
binding to complementary sites on target mRNA 3’UTRs 
 
  
Key points 
 Even though most of the noncoding RNA (ncRNA) species were initially dismissed as 
products of spurious transcription, a wide spectrum of ncRNA regulatory mechanisms is 
now emerging. 
 ncRNA expression in brain is dynamically regulated in an activity-dependent and 
spatiotemporally controlled manner suggesting very precise regulatory roles in brain 
development and function. 
 The intricate transcriptional output of genomic loci may impact human brain evolution 
and explain specific vulnerability to neurodegeneration. 
 ncRNA expression and function is perturbed in neurodegenerative disorders and genetic 
variations in ncRNA networks can be associated to disease risk. 
 Understanding the mechanistic aspects of ncRNA function in the central nervous system 
and how ncRNA dysfunction may lead to neurodegenerative disorders is likely to offer 
new diagnostic and therapeutic approaches for these diseases. 
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